{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:06:05Z","timestamp":1768971965803,"version":"3.49.0"},"reference-count":26,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Type 2 diabetes mellitus (T2D) increases the risk of heart failure (HF) and chronic kidney disease (CKD). Nonetheless, evidence of cardiovascular (CV) prognosis is relatively scarce in young T2D patients. Purpose: To estimate the risk of all-cause death, CV death, and non-fatal major CV events (MACEs) in T2D patients younger than 65 years old. Methods: We designed a retrospective cohort study using incident cases of either T2D, HF, or CKD in the population aged 40\u201365 years, from 1st January 2000 to 31st December 2019. Each individual was followed for up to one year. The primary analysis consisted of survival analysis with Cox proportional hazards to compare one-year risk of all-cause death, CV death, and MACEs between T2D without HF or CKD (T2D), T2D with HF (T2D-HF), and T2D with CKD (T2D-CKD) groups. Results: A total of 14,986 incident adult diabetic patients from the last two decades in our institution were included with an average age at cohort inclusion of 55\u201358 years old. Glycemic control was similar among groups. The adjusted hazard ratio (HR) of one-year all-cause death was 2.77 (95% CI: 2.26\u20133.40) for T2D-HF and 3.09 (2.77\u20133.45) for T2D-CKD compared with the baseline T2D risk. The highest event rate (T2D-CKD) was 0.15 per person-year. The adjusted HR of one-year CV death was 2.75 (95% CI: 2.19\u20133.46) for T2D-CKD and 2.59 (1.72\u20133.91) for T2D-HF. The non-fatal MACE risk was significantly increased in T2D-HF or T2D-CKD compared with T2D (2.82 (CI95%: 2.34\u20133.41) for T2D-CKD vs. 1.90 (CI95%: 1.66\u20132.17) for T2D-CKD) with a 32% event rate in non-fatal MACEs. Conclusions: Coexistence of HF or CKD is associated with increased premature mortality as well as non-fatal CV events in T2D patients under 65 years old.<\/jats:p>","DOI":"10.3390\/jcm11082131","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T02:48:59Z","timestamp":1649731739000},"page":"2131","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Premature Mortality in Type 2 Diabetes Mellitus Associated with Heart Failure and Chronic Kidney Disease: 20 Years of Real-World Data"],"prefix":"10.3390","volume":"11","author":[{"given":"Cristina","family":"Gavina","sequence":"first","affiliation":[{"name":"Cardiology Department, Pedro Hispano Hospital, 4464-513 Matosinhos, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5299-9341","authenticated-orcid":false,"given":"Daniel Seabra","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, 4050-313 Porto, Portugal"}]},{"given":"Daniel Martinho","family":"Dias","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, 4050-313 Porto, Portugal"},{"name":"Family Health Unit Ao Encontro da Sa\u00fade, ACeS Grande Porto I-Santo Tirso\/Trofa, 4745-559 Trofa, Portugal"}]},{"given":"Filipa","family":"Bernardo","sequence":"additional","affiliation":[{"name":"Medical Department, AstraZeneca, 2730-097 Barbarena, Portugal"}]},{"given":"Hugo","family":"Martinho","sequence":"additional","affiliation":[{"name":"Medical Department, AstraZeneca, 2730-097 Barbarena, Portugal"}]},{"given":"Jo\u00e3o","family":"Couceiro","sequence":"additional","affiliation":[{"name":"Medical Department, AstraZeneca, 2730-097 Barbarena, Portugal"}]},{"given":"Carla","family":"Santos-Ara\u00fajo","sequence":"additional","affiliation":[{"name":"Nephrology Department, Pedro Hispano Hospital, 4464-513 Matosinhos, Portugal"},{"name":"UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7430-6297","authenticated-orcid":false,"given":"Ricardo Jorge","family":"Dinis-Oliveira","sequence":"additional","affiliation":[{"name":"TOXRUN\u2013Toxicology Research Unit, University Institute of Health Sciences, Advanced Polytechnic and University Cooperative (CESPU), CRL, 4585-116 Gandra, Portugal"},{"name":"Department of Public Health and Forensic Sciences and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"},{"name":"UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0998-6000","authenticated-orcid":false,"given":"Tiago","family":"Taveira-Gomes","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2018). Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care, 41, 917\u2013928.","DOI":"10.2337\/dci18-0007"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of Type 2 Diabetes-Global Burden of Disease and Forecasted Trends","volume":"10","author":"Khan","year":"2020","journal-title":"J. Epidemiol. Glob. Health"},{"key":"ref_4","first-page":"19","article-title":"Diabetes: Factos e n\u00fameros 2016, 2017 e 2018","volume":"15","author":"Raposo","year":"2020","journal-title":"Rev. Port. Diabetes"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Fontes-Carvalho, R., Santos-Ferreira, D., Raz, I., Marx, N., Ruschitzka, F., and Cosentino, F. (2021). Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: Two faces of the same coin. Eur. J. Prev. Cardiol., zwab034.","DOI":"10.1093\/eurjpc\/zwab034"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e003316","DOI":"10.1161\/CIRCHEARTFAILURE.116.003316","article-title":"Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease: A Clinical Conundrum","volume":"9","author":"Aguilar","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Severino, P., D\u2019Amato, A., Prosperi, S., Fanisio, F., Birtolo, L.I., Costi, B., Netti, L., Chimenti, C., Lavalle, C., and Maestrini, V. (2021). Myocardial Tissue Characterization in Heart Failure with Preserved Ejection Fraction: From Histopathology and Cardiac Magnetic Resonance Findings to Therapeutic Targets. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147650"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/2040622314548679","article-title":"Early onset type 2 diabetes: Risk factors, clinical impact and management","volume":"5","author":"Wilmot","year":"2014","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.2337\/diacare.26.11.2999","article-title":"Complications in young adults with early-onset type 2 diabetes: Losing the relative protection of youth","volume":"26","author":"Hillier","year":"2003","journal-title":"Diabetes Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00125-020-05319-w","article-title":"Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: Systematic review and meta-analyses","volume":"64","author":"Nanayakkara","year":"2021","journal-title":"Diabetologia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.21037\/cdt.2018.09.04","article-title":"Implications of the growing burden of diabetes for premature cardiovascular disease mortality and the attainment of the Sustainable Development Goal target 3.4","volume":"9","author":"Wou","year":"2019","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/XCE.0000000000000210","article-title":"Estimating life years lost to diabetes: Outcomes from analysis of National Diabetes Audit and Office of National Statistics data","volume":"9","author":"Heald","year":"2020","journal-title":"Cardiovasc. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pcad.2019.07.003","article-title":"Diabetes, heart failure, and renal dysfunction: The vicious circles","volume":"62","author":"Braunwald","year":"2019","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cardfail.2019.05.007","article-title":"Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America","volume":"25","author":"Dunlay","year":"2019","journal-title":"J. Card. Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/sj.ki.5001794","article-title":"Predicting initiation and progression of chronic kidney disease: Developing renal risk scores","volume":"70","author":"Taal","year":"2006","journal-title":"Kidney Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/01.ASN.0000070147.10399.9E","article-title":"Risk Factors for Progressive Chronic Kidney Disease","volume":"14","author":"McClellan","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/17512433.2022.2051480","article-title":"Growing role of SGLT2i in heart failure: Evidence from clinical trials","volume":"15","author":"Varadhan","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s13300-022-01204-4","article-title":"Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors","volume":"13","author":"Heath","year":"2022","journal-title":"Diabetes Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sundstr\u00f6m, J., Bodegard, J., Bollmann, A., Vervloet, M.G., Mark, P.B., Karasik, A., Taveira-Gomes, T., Botana, M., Birkeland, K.I., and Thuresson, M. (2022). Prevalence, outcomes, and cost of CKD in a contemporary population of 2\u00b74 million patients from 11 countries: The CaReMe CKD study. Prepr. Lancet.","DOI":"10.2139\/ssrn.4000580"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/8\/2131\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:51:52Z","timestamp":1760136712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/8\/2131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["jcm11082131"],"URL":"https:\/\/doi.org\/10.3390\/jcm11082131","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]}}}